A256840 Stock Overview
Engages in the research and development, production, and sale of biomaterials in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A256840 from our risk checks.
BNC Korea Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,190.00 |
| 52 Week High | ₩9,410.00 |
| 52 Week Low | ₩3,300.00 |
| Beta | 0.91 |
| 11 Month Change | -25.31% |
| 3 Month Change | -34.33% |
| 1 Year Change | 21.27% |
| 33 Year Change | -77.89% |
| 5 Year Change | 53.48% |
| Change since IPO | 64.31% |
Recent News & Updates
BNC Korea (KOSDAQ:256840) Could Easily Take On More Debt
Oct 23
BNC Korea's (KOSDAQ:256840) Performance Raises Some Questions
Apr 01
Shareholder Returns
| A256840 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -8.4% | -5.8% | -2.8% |
| 1Y | 21.3% | 28.2% | -3.4% |
Return vs Industry: A256840 underperformed the KR Biotechs industry which returned 30.2% over the past year.
Return vs Market: A256840 exceeded the KR Market which returned -4.4% over the past year.
Price Volatility
| A256840 volatility | |
|---|---|
| A256840 Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A256840 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A256840's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 193 | Wan-Gyu Choi | www.bnckorea.co.kr |
BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials in South Korea. The company offers HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, ChungA-an, CUTEGEL-M, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration. It also provides Hibarry, a dressing for deep-cavity wounds that is used to reduce adhesion of the spinal cord during surgery; GENTA Q, a white collagen sponge, which is used to protect wounds by preventing contamination of wounds; and beauty solutions, face mask gels, mils cleansing foams, and brightening peeling gels.
BNC Korea Co., Ltd. Fundamentals Summary
| A256840 fundamental statistics | |
|---|---|
| Market cap | ₩278.40b |
| Earnings (TTM) | ₩21.33b |
| Revenue (TTM) | ₩83.78b |
13.1x
P/E Ratio3.3x
P/S RatioIs A256840 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A256840 income statement (TTM) | |
|---|---|
| Revenue | ₩83.78b |
| Cost of Revenue | ₩45.84b |
| Gross Profit | ₩37.94b |
| Other Expenses | ₩16.60b |
| Earnings | ₩21.33b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 321.07 |
| Gross Margin | 45.28% |
| Net Profit Margin | 25.46% |
| Debt/Equity Ratio | 4.2% |
How did A256840 perform over the long term?
See historical performance and comparison